These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 9811443)
1. The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase-2 and 9. Clegg PD; Jones MD; Carter SD J Vet Pharmacol Ther; 1998 Oct; 21(5):406-13. PubMed ID: 9811443 [TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases 2 and 9 in equine synovial fluids. Clegg PD; Coughlan AR; Riggs CM; Carter SD Equine Vet J; 1997 Sep; 29(5):343-8. PubMed ID: 9306059 [TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-2 and -9 are activated in joint diseases. Clegg PD; Carter SD Equine Vet J; 1999 Jul; 31(4):324-30. PubMed ID: 10454092 [TBL] [Abstract][Full Text] [Related]
4. The effect of drugs used in the treatment of osteoarthrosis on stromelysin (proteoglycanase) of equine synovial cell origin. May SA; Hooke RE; Lees P Equine Vet J Suppl; 1988 Sep; (6):28-32. PubMed ID: 9079060 [TBL] [Abstract][Full Text] [Related]
5. Characterisation of equine matrix metalloproteinase 2 and 9; and identification of the cellular sources of these enzymes in joints. Clegg PD; Burke RM; Coughlan AR; Riggs CM; Carter SD Equine Vet J; 1997 Sep; 29(5):335-42. PubMed ID: 9306058 [TBL] [Abstract][Full Text] [Related]
6. Recombinant equine interleukin-1beta induces putative mediators of articular cartilage degradation in equine chondrocytes. Tung JT; Fenton JI; Arnold C; Alexander L; Yuzbasiyan-Gurkan V; Venta PJ; Peters TL; Orth MW; Richardson DW; Caron JP Can J Vet Res; 2002 Jan; 66(1):19-25. PubMed ID: 11858644 [TBL] [Abstract][Full Text] [Related]
7. Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. Imai K; Ohta S; Matsumoto T; Fujimoto N; Sato H; Seiki M; Okada Y Am J Pathol; 1997 Jul; 151(1):245-56. PubMed ID: 9212749 [TBL] [Abstract][Full Text] [Related]
8. Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis. Vinardell T; Dejica V; Poole AR; Mort JS; Richard H; Laverty S Osteoarthritis Cartilage; 2009 Mar; 17(3):375-83. PubMed ID: 18809344 [TBL] [Abstract][Full Text] [Related]
9. Collagenase-1 (MMP-1) activity in equine synovial fluid: influence of age, joint pathology, exercise and repeated arthrocentesis. Brama PA; van den Boom R; DeGroott J; Kiers GH; van Weeren PR Equine Vet J; 2004 Jan; 36(1):34-40. PubMed ID: 14756369 [TBL] [Abstract][Full Text] [Related]
10. Effect of glucosamine on interleukin-1-conditioned articular cartilage. Fenton JI; Chlebek-Brown KA; Caron JP; Orth MW Equine Vet J Suppl; 2002 Sep; (34):219-23. PubMed ID: 12405690 [TBL] [Abstract][Full Text] [Related]
11. Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific. Freemont AJ; Hampson V; Tilman R; Goupille P; Taiwo Y; Hoyland JA Ann Rheum Dis; 1997 Sep; 56(9):542-9. PubMed ID: 9370879 [TBL] [Abstract][Full Text] [Related]
12. Use of an antineoepitope antibody for identification of type-II collagen degradation in equine articular cartilage. Billinghurst RC; Buxton EM; Edwards MG; McGraw MS; McIlwraith CW Am J Vet Res; 2001 Jul; 62(7):1031-9. PubMed ID: 11453476 [TBL] [Abstract][Full Text] [Related]
13. Concentration-dependent effects of tiludronate on equine articular cartilage explants incubated with and without interleukin-1β. Duesterdieck-Zellmer KF; Driscoll N; Ott JF Am J Vet Res; 2012 Oct; 73(10):1530-9. PubMed ID: 23013178 [TBL] [Abstract][Full Text] [Related]
14. Microscopic localization of active gelatinases in equine osteochondritis dissecans (OCD) cartilage. Al-Hizab F; Clegg PD; Thompson CC; Carter SD Osteoarthritis Cartilage; 2002 Aug; 10(8):653-61. PubMed ID: 12479388 [TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Tetlow LC; Adlam DJ; Woolley DE Arthritis Rheum; 2001 Mar; 44(3):585-94. PubMed ID: 11263773 [TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase activity in equine synovial fluid: influence of age, osteoarthritis, and osteochondrosis. Brama PA; TeKoppele JM; Beekman B; van Weeren PR; Barneveld A Ann Rheum Dis; 1998 Nov; 57(11):697-9. PubMed ID: 9924215 [TBL] [Abstract][Full Text] [Related]
17. [Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study]. Matsumoto F; Uzuki M; Kaneko C; Rikimaru A; Kokubun S; Sawai T Ryumachi; 1997 Oct; 37(5):688-95. PubMed ID: 9396371 [TBL] [Abstract][Full Text] [Related]
18. Metalloproteinases and tumor necrosis factor-alpha activities in synovial fluids of horses: correlation with articular cartilage alterations. Jouglin M; Robert C; Valette JP; Gavard F; Quintin-Colonna F; Denoix JM Vet Res; 2000; 31(5):507-15. PubMed ID: 11050746 [TBL] [Abstract][Full Text] [Related]
19. Effects of dosage titration of methylprednisolone acetate and triamcinolone acetonide on interleukin-1-conditioned equine articular cartilage explants in vitro. Dechant JE; Baxter GM; Frisbie DD; Trotter GW; McIlwraith CW Equine Vet J; 2003 Jul; 35(5):444-50. PubMed ID: 12875321 [TBL] [Abstract][Full Text] [Related]
20. MT3-MMP (MMP-16) is downregulated by in vitro cytokine stimulation of cartilage, but unaltered in naturally occurring equine osteoarthritis and osteochondrosis. Garvican ER; Vaughan-Thomas A; Redmond C; Clegg PD Connect Tissue Res; 2008; 49(2):62-7. PubMed ID: 18382891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]